Due to an editing error, yesterday's BIO SmartBrief incorrectly identified Mark McClellan. McClellan is the administrator of the Centers for Medicare and Medicaid Services. SmartBrief regrets the error.
With underwriting by Goldman Sachs JBWere, Acrux shares sold quickly, followed by an additional opening, testament to the promise of its technology used for spray-on skin-absorbent drugs. The novel drug-delivery system is being tested by Vivus for use with its female libido-lifting treatment and has been licensed to Australia's CSL and America's Eli Lilly for various therapeutic applications.
Celera Genomics Group and Genentech have signed an agreement to share possible therapeutic discoveries, with Genentech financing development of protein-based drugs produced by Celera for treating cancer. Celera has made two similar arrangements with other pharmaceutical or biotechnology companies.
According to the head of Ontario Agri-Foods Technologies, bioengineered spiderwebs may one day be used as gas tanks, plastic cups may be derived from cornstarch or cars could be powered by corn cob derivatives. Saying agricultural biotechnology goes beyond food, the Agri-Foods scientist called it "a whole new world," when researchers unleash their imaginations, leading to even newer applications for their discoveries.
A leader in the country's green revolution said because crop yields are too low to feed the starving populations of developing countries, the two farming technologies -- organics and bioengineering -- need to be harmonized to raise production and prevent malnutrition. He also told the International Crop Science Congress new farming technologies should be available to "all economically underprivileged farming families."
The Accreditation Council for Continuing Medical Education is expected to announce new rules today governing what physicians are allowed to discuss when teaching CME courses. If an instructor has any kind of financial ties to a drug company, he must disclose those ties and a third party -- with no connection to the company -- would dictate which recommendations the physician could make. The new rule was endorsed by the American Medical Association.